674 related articles for article (PubMed ID: 34365035)
1. Epigenetic strategies to boost CAR T cell therapy.
Akbari B; Ghahri-Saremi N; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Mol Ther; 2021 Sep; 29(9):2640-2659. PubMed ID: 34365035
[TBL] [Abstract][Full Text] [Related]
2. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J
Front Immunol; 2020; 11():702. PubMed ID: 32391013
[TBL] [Abstract][Full Text] [Related]
3. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
4. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Front Immunol; 2021; 12():738456. PubMed ID: 34721401
[TBL] [Abstract][Full Text] [Related]
5. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cell persistence and memory cell formation.
McLellan AD; Ali Hosseini Rad SM
Immunol Cell Biol; 2019 Aug; 97(7):664-674. PubMed ID: 31009109
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and epigenetic orchestration of (CAR) T cell fate and function.
Akbari B; Hosseini Z; Shahabinejad P; Ghassemi S; Mirzaei HR; O'Connor RS
Cancer Lett; 2022 Dec; 550():215948. PubMed ID: 36209973
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of response and resistance to CAR T cell therapies.
Berger TR; Maus MV
Curr Opin Immunol; 2021 Apr; 69():56-64. PubMed ID: 33752101
[TBL] [Abstract][Full Text] [Related]
10. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
12. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
13. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
14. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
16. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
18. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
Ahn T; Bae EA; Seo H
Mol Ther; 2024 Jun; 32(6):1617-1627. PubMed ID: 38582965
[TBL] [Abstract][Full Text] [Related]
19. The role of exhaustion in CAR T cell therapy.
Delgoffe GM; Xu C; Mackall CL; Green MR; Gottschalk S; Speiser DE; Zehn D; Beavis PA
Cancer Cell; 2021 Jul; 39(7):885-888. PubMed ID: 34256903
[TBL] [Abstract][Full Text] [Related]
20. Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
